secwatch.observer — SEC 8-K summary
======================================

Issuer:     Telomir Pharmaceuticals, Inc. (TELO)
CIK:        0001971532
Form:       8-K
Filed at:   2025-10-08T23:59:59+00:00
Accession:  0001493152-25-017422
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Telomir-1 selectively kills triple-negative breast cancer cells in lab studies
------------------------------------------------------------------------------

- Telomir-1 produced concentration-dependent reduction in TNBC cell survival; iron addition reversed effect, confirming iron-dependent mechanism.
- Compound targets aggressive TNBC cells' metabolic reliance on iron, potentially sparing healthy tissue due to differing iron management.
- Findings link Telomir-1's effect to Jumonji domain histone demethylases (KDM5A/B, KDM6B) involved in cancer aggression and therapy resistance.
- Company plans to expand studies to pancreatic and leukemia models, and conduct animal studies ahead of IND submission.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1971532/000149315225017422/0001493152-25-017422-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1971532/000149315225017422/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-017422

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer